CPP Investments related stories
All articles and analysis
CalPERS' plan to leverage its portfolio: Three things to knowThe pension giant plans to leverage up to $80bn of its total portfolio to tap opportunities during the market downturn. Here’s how it could do it.
Perfect Day expands Series C round with CPPIB-led tranchePerfect Day, an Emeryville, California-based provider of animal-free dairy products, has closed a new tranche to its Series C financing, bringing the total raised to US$300 million.
Side Letter: Which placement agents took PPP, CalPERS' leverage, Waterland IR headState aid has been mostly ruled out for PE firms in the US, but data show placement agents have benefited from loans. Here's today's brief, for our valued subscribers only.
UK's 'ambiguous' takeover rules could stifle healthcare dealsThe rules, which came into force on 23 June, will enable the UK government to intervene in foreign takeovers of British companies deemed critical in public health emergencies.
Global Investor 100: CPPIB's Feeney on managing the top-ranked PE portfolioThe $324bn Canadian pension plan’s private equity portfolio stands head and shoulders above the competition in our inaugural ranking. Global head of private equity Shane Feeney talks through its approach to the asset class.
Global Investor 100: Who else makes the top 10?Explore the firms that make up the rest of our Global Investor 100 top 10.
The latest way to stay connected with LPs? Host a TV showEQT's television show-style annual investor meeting in June shows the coronavirus crisis has led to novel ways of staying in touch with LPs.
Fusion Pharmaceuticals goes public, expects to raise $212mFusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share.
Sana Biotechnology picks up $700m in VC financingSana Biotechnology, a Seattle, Washington-based company focused on creating and delivering engineered cells as medicines, has raised more than US$700 million.
VC-backed Fusion Pharmaceuticals seeks $125m from IPO: reportCanadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.